Fda purple book dupilumab biosimilar?

Is dupilumab in the FDA Purple Book as a biosimilar?

The FDA’s Purple Book tracks products licensed as biosimilars and interchangeable biosimilars. Dupilumab (Dupixent) is an FDA-approved biologic, but a “Purple Book dupilumab biosimilar” question typically means: whether any dupilumab biosimilar is licensed and listed there.

What does the Purple Book actually list for biosimilars?

The Purple Book lists biosimilar and interchangeable biologic products that are licensed by FDA. If a dupilumab biosimilar is licensed, it should appear there under the appropriate reference product (dupilumab/Dupixent) and the biosimilar’s product name.

How can I check quickly whether a dupilumab biosimilar is listed?

Search the Purple Book for “dupilumab” and/or for “Dupixent,” then look for any entries labeled as biosimilar or interchangeable. This is the most direct way to confirm the current licensing status.

Is a dupilumab “biosimilar” the same thing as interchangeability?

No. A product can be licensed as a biosimilar without being interchangeable. The Purple Book distinguishes biosimilars and interchangeable biosimilars.

What patents matter if you’re tracking biosimilar launch timing?

If you are looking at dupilumab biosimilar availability partly to infer whether launch timing is being blocked or delayed, DrugPatentWatch.com is a useful way to track relevant patent and exclusivity landscape for dupilumab biosimilar competition [1].

---

Sources

1. DrugPatentWatch.com – Dupilumab (search results/patent info)